Cures Within Reach Selected Seven More Clinical Trials to Address Factors that Lead to High Disease Burden in Low and Lower-Middle Income Countries

CHICAGO - Feb. 11, 2026 - PRLog -- Cures Within Reach (CWR), a global nonprofit that identifies and funds clinical trials testing approved therapies for unsolved diseases, has selected for funding seven additional clinical trials to de-risk potential therapeutic options that address high disease burden for patients in low and lower-middle income countries (LMICs), including four trials already underway. With funding from Coefficient Giving (previously Open Philanthropy), these clinical trials are led by LMIC-based researchers to impact LMIC-based patients by using readily available generic medicines, nutraceuticals and/or indigenous medicines. In addition, these trials include funding for important community engagement activities alongside each selected trial to involve trusted community leaders and organizations that bring clinical research to patients within their respective communities.

"CWR is committed to addressing the significant need to build research capacity and bridging the funding gap in LMICs by investing in transformative clinical research," said Barbara Goodman, president and CEO of Cures Within Reach. "Since 2020, we have grown the number of LMIC-based clinical trials, and in 2025 we are adding a record of seven high-potential repurposing proof-of-concept studies that bring our portfolio to a total of 26 trials. Through our partnership with Coefficient Giving, we are empowering LMIC-based clinical researchers which in turn advances local healthcare infrastructure and elevates access to medicines for underserved populations."

"Coefficient Giving is focused on the speed to impact to benefit populations in low and lower-middle income countries. Cures Within Reach's model helps us find innovative investigators within these regions who are best positioned to serve their local patient communities," said Ray Kennedy, Senior Program Officer for Coefficient Giving's Science and Global Health R&D Fund. "We have seen these researchers begin with a proof-of-concept trial, with funding from CWR, now leading larger trials with access to funds they might not have had otherwise. CWR's model builds sustainable research capacity and accelerates research directed toward underserved populations, which contributes to our goal of fostering a more equitable global health ecosystem."

In 2025, CWR selected the following seven LMIC-based clinical trials already underway or expected to start soon:

• Reducing Small Vulnerable Newborns with an Antimalarial Drug in Bangladesh at International Centre for Diarrhoeal Disease Research, Bangladesh
• Helping Recovery After Traumatic Brain Injury with Vitamin D3 in Nigeria at Lagos State University College of Medicine
• Improving Pre-Cancerous Lesion Treatment Among HIV-Positive Women in Kenya at Maseno University
• Improving Breast Cancer Surgery Outcomes with Doxycycline in Tanzania at Muhimbili University of Health and Allied Sciences
• Slowing Rheumatic Heart Disease Progression with Losartan in India at Translational Health Science and Technology Institute
• Using N-Acetylcysteine to Treat Early-Onset Preeclampsia in Nigeria at University of Lagos
• Treating Cutaneous Leishmaniasis with a Topical Antiseptic at University of Nigeria (https://www.cureswithinreach.org/2026/01/26/treating-cutaneous-leishmaniasis-with-a-topical-antiseptic-in-nigeria/)

These seven bring CWR's LMIC portfolio to 26 clinical trials, including 16 ongoing trials, seven completed and three trials starting soon. Of the seven completed LMIC-based clinical trials that CWR funded, six have seen successful clinical results – a significantly high level of clinical success for these proof-of-concept trials, several with publications or pending publications, catalytic funding raised and follow-on trials underway.

About Cures Within Reach
Cures Within Reach (CWR) is a US-based nonprofit leader testing already approved therapies for unsolved diseases by leveraging the speed, safety and cost-effectiveness of repurposing: driving more treatments to more patients more quickly. CWR provides seed funds for pivotal studies that, when successful, allow a catalytic effect of follow-on funding for trials that build clinical evidence for physicians to make decisions with their patients (called off-label use) or for regulatory approval. CWR's 2026 initiatives include validating AI drug-disease predictions and clinical trials impacting veterans, pediatrics and LMIC-based patients. CWR currently has a global portfolio of 50 funded trials at 40 institutions in 33 diseases in 12 countries. Visit cureswithinreach.org (http://www.cureswithinreach.org/). Contact Research@CuresWithinReach.org for more information.